CROs ‘combine forces’ to meet demand from biopharma customers

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Kritchanut)
(Image: Getty/Kritchanut)

Related tags: CRO, Biopharmaceutical, Clinical trials, Patient recruitment

Veristat’s acquisition of Topstone enhances the CRO’s capabilities within several areas and boosts its employee count to 300 across six offices.

Veristat, a full-service clinical research organization (CRO) based in Southborough, MA has completed its acquisition of Topstone Research, a Canadian-based specialty contract research organization (CRO) providing Phase II-IV services.

Veristat CEO Patrick Flanagan said the company had been looking to broaden its clinical operations capabilities. “Our customers are moving their therapies to pivotal trials quickly and have continued to ask us for more of the services we provide and additional, complementary clinical services,”​ he told us.

The acquisition bolsters Veristat’s core therapeutic areas of excellence and broadens its therapeutic expertise with respiratory and dermatology, Flanagan said.

“Additionally, Topstone adds patient recruitment and retention support, a site engagement team, and medical safety and monitoring expertise to support investigators and sites with study conduct in an ethical, patient safety-focused approach,”​ he added.

Topstone will be integrated Veristat’s current monitoring and site management organization transitioning to the Veristat name and brand over the coming months.

The combined team now consists of nearly 300 experts located in six offices.

Topstone’s current CEO, Shaheen Limbada, will become Veristat’s executive vice president of clinical operations with both companies’ clinical operations teams uniting under his leadership.  

As for next steps, Flanagan said the acquisition is part of the growth strategy that Veristat will continue to pursue to improve and expand its capabilities to new service offerings and geographies, “to serve the growing demands of our emerging and small to mid-sized biopharmaceutical customers.”

“Where an opportunity presents itself to combine with a company which shares Veristat’s mission to help clients develop life-enhancing therapies and our commitment to delivering high-quality services which make a difference we will seek to combine forces,”​ he said.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more